A regulatory Apologia - A review of placebo-controlled studies in regulatory submissions of new-generation antidepressants

European Neuropsychopharmacology

Volumn 18, Issue 9, 2008, Pages 623-627

  Melander, Hans ^a   Salmonson, Tomas ^a,b   Abadie, Eric ^b,c   van Zwieten Boot, Barbara ^b,d  

^a MEDICAL PRODUCTS AGENCY   (Sweden)

^b EMEA   (United Kingdom)

^c AFSSAPS   (France)

^d MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

Clinical relevance; Major depression; Placebo

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG RESEARCH; DRUG RESPONSE; HAMILTON SCALE; HUMAN; PRIORITY JOURNAL; SAMPLE SIZE;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSION; DRUG APPROVAL; HUMANS; PLACEBOS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 48749084610     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.06.003     Document Type: Article

References (9)

1. Angst J. Severity of depression and benzodiazepine co-medication in relationship to efficacy of antidepressants in acute trials: a meta-analysis moclobemide trials. Hum. Psychopharmacol. 8 (1993) 401-407
2. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin. Trials 7 (1986) 177-188
3. Kahn A., Leventhal R., Kahn S., et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J. Clin. Psychopharmacol. 22 (2002) 40-45
4. Kirsch I., and Saperstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prev. Treat. 1 (1998). http://www.journals.apa.org/prevention/volume1/pre001002a.html Article 0002a. Available: http://www.journals.apa.org/prevention/volume1/pre001002a.html
5. Kirsch I., Moore T.J., Scoboria A., and Nicholls S.S. The emperor's new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev. Treat. 5 (2002). http://www.journals.apa.org/prevention/volume5/pre0050023a.html Article 23. Available: http://www.journals.apa.org/prevention/volume5/pre0050023a.html
6. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 5 2 (2008) e45 10.1371/journal. pmed.0050045
7. Melander H., Ahlqvist-Rastad J., Meijer G., and Beermann B. Evidenced b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326 (2003) 1171-1173
8. National Institute for Clinical Excellence. Depression: Management of Depression in Primary and Secondary Care. Clinical practice guideline vol 23 (2004), National Institue for Clinical Excellence, London
9. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., and Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 358 (2008) 252-260